Molecular Imaging for Efficacy of Pharmacologic Intervention in Myocardial Remodeling

JACC: Cardiovascular Imaging

Volumn 2, Issue 2, 2009, Pages 187-198

  van den Borne, Susanne W M ^a,b   Isobe, Satoshi ^a   Zandbergen, H Reinier ^b   Li, Peng ^a   Petrov, Artiom ^a   Wong, Nathan D ^a   Fujimoto, Shinichiro ^a   Fujimoto, Ai ^a   Lovhaug, Dagfinn ^c   Smits, Jos F M ^b   Daemen, Mat J A P ^b   Blankesteijn, W Matthijs ^b   Reutelingsperger, Chris ^b   Zannad, Faiez ^d   Narula, Navneet ^a   Vannan, Mani A ^a   Pitt, Bertram ^e   Hofstra, Leonard ^b   Narula, Jagat ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c GE HEALTHCARE   (Norway)

^d UNIVERSITÉ DE LORRAINE   (France)

^e UNIVERSITY OF MICHIGAN   (United States)

Author keywords

angiotensin receptors; angiotensin converting enzyme; collagen; heart failure; mineralocorticoids; radionuclide imaging; remodeling

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ARGINYLGLYCYLASPARTIC ACID; CAPTOPRIL; COLLAGEN; COLLAGEN FIBER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN; SPIRONOLACTONE; TECHNETIUM 99M; TRACER;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ECHOCARDIOGRAPHY; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; HEART MUSCLE FIBROSIS; HISTOPATHOLOGY; MALE; MOLECULAR IMAGING; MOUSE; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; SCINTISCANNING; SURVIVAL; TISSUE REPAIR;

ALDOSTERONE ANTAGONISTS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CAPTOPRIL; CARBOCYANINES; CARDIOVASCULAR AGENTS; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; ECHOCARDIOGRAPHY; FIBRILLAR COLLAGENS; FIBROBLASTS; FIBROSIS; LOSARTAN; MICE; MYOCARDIAL INFARCTION; MYOCARDIUM; OLIGOPEPTIDES; PREDICTIVE VALUE OF TESTS; SPIRONOLACTONE; TECHNETIUM; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 59649126215     PISSN: 1936878X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcmg.2008.11.011     Document Type: Article

References (35)

1. Weber K.T., and Brilla C.G. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 83 (1991) 1849-1865
2. Weber K.T., Anversa P., Armstrong P.W., et al. Remodeling and reparation of the cardiovascular system. J Am Coll Cardiol 20 (1992) 3-16
3. Pitt B. Aldosterone blockade in patients with systolic left ventricular dysfunction. Circulation 108 (2003) 1790-1794
4. Shirani J., Narula J., Eckelman W.C., Narula N., and Dilsizian V. Early imaging in heart failure: exploring novel molecular targets. J Nucl Cardiol 14 (2007) 100-110
5. Volders P.G., Willems I.E., Cleutjens J.P., Arends J.W., Havenith M.G., and Daemen M.J. Interstitial collagen is increased in the non-infarcted human myocardium after myocardial infarction. J Mol Cell Cardiol 25 (1993) 1317-1323
6. Cleutjens J.P., Blankesteijn W.M., Daemen M.J., and Smits J.F. The infarcted myocardium: simply dead tissue, or a lively target for therapeutic interventions. Cardiovasc Res 44 (1999) 232-241
7. Anversa P., and Capasso J.M. Cardiac hypertrophy and ventricular remodeling. Lab Invest 64 (1991) 441-445
8. Pitt B., Poole-Wilson P.A., Segal R., et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 355 (2000) 1582-1587
9. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316 (1987) 1429-1435
10. Cohn J.N., Johnson G., Ziesche S., et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 325 (1991) 303-310
11. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 (1999) 709-717
12. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., and Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342 (2000) 145-153
13. Pfeffer M.A., Braunwald E., Moye L.A., et al., The SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 327 (1992) 669-677
14. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325 (1991) 293-302
15. Pitt B., Remme W., Zannad F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 (2003) 1309-1321
16. Pfeffer M.A., Swedberg K., Granger C.B., et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362 (2003) 759-766
17. Cohn J.N., and Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345 (2001) 1667-1675
18. McNamara D.M., Holubkov R., Janosko K., et al. Pharmacogenetic interactions between beta-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. Circulation 103 (2001) 1644-1648
19. Small K.M., Wagoner L.E., Levin A.M., Kardia S.L., and Liggett S.B. Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med 347 (2002) 1135-1142
20. van den Borne S.W.M., Isobe S., Verjans J., et al. Molecular imaging of interstitial alterations in remodeling myocardium after myocardial infarction. J Am Coll Cardiol 52 (2008) 2017-2028
21. Verjans J.W.H., Lovhaug D., Narula N., et al. Noninvasive imaging of angiotensin receptores after myocardial infarction. J Am Coll Cardiol Cardiovasc Imaging 1 (2008) 354-362
22. Schiller N.B., Shah P.M., Crawford M., et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 2 (1989) 358-367
23. Tonti G., Verjans J., Pedrizzetti G., et al. Measurement of apical torsion in mitochrondrial cardiomyopathy using a novel B-mode, automated tracking algorithm. J Am Coll Cardiol 45 (2005) 305A
24. Whittaker P., Kloner R.A., Boughner D.R., and Pickering J.G. Quantitative assessment of myocardial collagen with picrosirius red staining and circularly polarized light. Basic Res Cardiol 89 (1994) 397-410
25. MacKenna D.A., Omens J.H., McCulloch A.D., and Covell J.W. Contribution of collagen matrix to passive left ventricular mechanics in isolated rat hearts. Am J Physiol 266 (1994) H1007-H1018
26. Verjans J.W., Wolters S.L., Lax M., et al. Imaging avb3/b5 Integrin Upregulation in Patients After Myocardial Infarction. Circulation 116 (2007) II3288
27. Poulsen S.H., Host N.B., Jensen S.E., and Egstrup K. Relationship between serum amino-terminal propeptide of type III procollagen and changes of left ventricular function after acute myocardial infarction. Circulation 101 (2000) 1527-1532
28. Cicoira M., Rossi A., Bonapace S., et al. Independent and additional prognostic value of aminoterminal propeptide of type III procollagen circulating levels in patients with chronic heart failure. J Card Fail 10 (2004) 403-411
29. Radovan J., Vaclav P., Petr W., et al. Changes of collagen metabolism predict the left ventricular remodeling after myocardial infarction. Mol Cell Biochem 293 (2006) 71-78
30. Zannad F., Alla F., Dousset B., Perez A., Pitt B., and Rales Investigators. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Circulation 102 (2000) 2700-2706
31. Zannad F., and Radauceanu A. Effect of MR blockade on collagen formation and cardiovascular disease with a specific emphasis on heart failure. Heart Fail Rev 10 (2005) 71-78
32. McMurray J.J., Ostergren J., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362 (2003) 767-771
33. Yusuf S., Teo K.K., Pogue J., et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358 (2008) 1547-1559
34. van Amerongen M.J., Harmsen M.C., van Rooijen N., Petersen A.H., and van Luyn M.J. Macrophage depletion impairs wound healing and increases left ventricular remodeling after myocardial injury in mice. Am J Pathol 170 (2007) 818-829
35. Dai W., Wold L.E., Dow J.S., and Kloner R.A. Thickening of the infarcted wall by collagen injection improves left ventricular function in rats: a novel approach to preserve cardiac function after myocardial infarction. J Am Coll Cardiol 46 (2005) 714-719